Market news — every asset we track

Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will...

Sep 2Yahoo Finance

IMUX

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Incyte (INCY) and Eli Lilly & Co (LLY)

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Sep 2The Globe and Mail

IMUX

INCY

LLY

Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual research and development (R&D) day focused on relapsing multiple sclerosis (MS) on Wednesday, September 9, 2026, at 11:00 am ET.

Sep 2Yahoo Finance

IMUX

Immunic appoints Chitrang Davé as chief data and digital officer

Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it has appointed Chitrang Davé as chief data and digital officer, effective August 30, creating a new executive role focused on data, analytics, artificial intelligence and digital strategy. Davé will report to CEO Erik Lundgren and join...

Sep 1finance.yahoo.com

IMUX

Roth Capital Partners Adjusts Price Target on Immunic to $29 From $19, Maintains Buy Rating

Immunic (IMUX) has an average rating of buy and mean price target of $43.09, according to analysts p

Sep 1Yahoo FinanceTEST

IMUX

Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating (NASDAQ:IMUX)

Aug 25Seeking Alpha

IMUX

Wedbush initiates Immunic stock with Outperform rating

Aug 17Investing.com

IMUX

Wedbush Initiates Immunic at Outperform With $45 Price Target

Immunic (IMUX) has an average rating of buy and mean price target of $41.90, according to analysts p

Aug 17finance.yahoo.com

IMUX

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Immunic (IMUX) points to a 163% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Aug 13Yahoo Finance

IMUX

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)

Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.

Aug 12The Globe and Mail

IMUX

LEGN

SGMT

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Aug 11Yahoo Finance

IMUX

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

Aug 11Yahoo Finance UK

IMUX

Immunic appoints Elena Ridloff to board of directors

Aug 10Investing.com

IMUX

Immunic Names CEO Erik Lundgren to Board

Detailed price information for Immunic Inc (IMUX-Q) from The Globe and Mail including charting and trades.

Jul 7The Globe and Mail

IMUX

This is the newest page. Registered accounts read further back.